Metastatic Merkel cell carcinoma and myasthenia gravis: contraindication for therapy with immune checkpoint inhibitors?
ConclusionsPatients with a preexisting MG can be considered for treatment with immune checkpoint inhibitors if they have a life-threatening cancer and if other effective, long-lasting treatment options are not available. The risks and benefits of therapy should be weighed in a multidisciplinary setting and should be discussed thoroughly with the patient. Exacerbation of underlying MG can be potentially life-threatening and requires close monitoring in collaboration with neuromuscular specialists.
Authors: Bondy SC, Campbell A Abstract Melatonin is well known as a neuroendocrine hormone that promotes sleep. However, the many other attributes of melatonin are less apparent and not as widely appreciated. The purpose of this review is to summarize the qualities of melatonin relating to immune function. The relevance of melatonin in partially or wholly restoring optimal function in a series of disorders related to immune dysfunction is addressed. This includes the potential relief of both autoimmune diseases and many other ailments involving abnormal immune responses, including the overall diminished effectivene...
Publication date: Available online 12 July 2020Source: Biochimica et Biophysica Acta (BBA) - General SubjectsAuthor(s): Sumit Sahni, Christoph Krisp, Mark P. Molloy, Christopher Nahm, Sarah Maloney, Josef Gillson, Anthony J. Gill, Jaswinder Samra, Anubhav Mittal
Analyst, 2020, Accepted Manuscript DOI: 10.1039/D0AN01011A, PaperXiaonan Gao, Congcong Zhao, Keyan Wei, Bo Hu, Yu-Qin Chen, Kehua Xu, Bo Tang The anticancer mechanism for reduced/oxidized ascorbic acid (AA/DHA) is of great significance for clinical cancer therapies. A pH controlled fluorescent nanocarrier was designed to targetable deliver AA and DHA into... The content of this RSS Feed (c) The Royal Society of Chemistry
Cancer therapies could potentially be more effective if their development took into account the cells that give rise to tumor-fighting cells.
A study suggests the potential for a noninvasive diagnostic that could detect tumors early and differentiate between disease types.
Better understanding the CD8+ T cells already present in tumors could be key to making immunotherapies work for more patients.
Publication date: Available online 12 July 2020Source: Pathology - Research and PracticeAuthor(s): Eric Gyan, Linda Ahenkorah Fondjo, William Owiredu, Andrew Jackson, Andrew Green
Publication date: Available online 11 July 2020Source: Pathology - Research and PracticeAuthor(s): Hyun Ji Son, Eun Ji Choi, Nam Jin Yoo, Sug Hyung Lee
Publication date: Available online 11 July 2020Source: Pathology - Research and PracticeAuthor(s): JE Ruisch, M Kloft, GE Fazzi, J Melenhorst, D Magee, HI Grabsch
Publication date: Available online 11 July 2020Source: Journal of Functional FoodsAuthor(s): Khalid Z. Masoodi, Wasia Wani, Zahoor A. Dar, Sheikh Mansoor, Syed Anam-ul-Haq, Iqra Farooq, Khursheed Hussain, Shafiq A. Wani, Firdos A. Nehvi, Nazeer Ahmed